Zimbabwe has rejected a major American health deal worth 367 million US dollars (272 million pounds) over five years because of Washington's demand for confidential data.
This move came to light after a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
An official representative has since clarified that the US was seeking health data for scientific study and profit but was unwilling to guarantee the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable process of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for more dialogue to reach a deal suitable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Context
This development follows a similar case in Kenya, where a court suspended a similar deal with the US following concerns were filed about the safety of Kenyans' health data.
After resuming office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had overseen aid for the US government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government deals to boost openness and responsibility.
As per statements, 16 nations in Africa have so far agreed to these new agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy via US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to share its biological resources and data over an extended period, without any corresponding promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our country would provide the raw materials for scientific discovery without any certainty that the final treatments would be available to our people if a new pandemic emerge."
Sovereignty and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were disrupting frameworks previously established through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to manage future pandemics.
"This mechanism is intended to ensure that when a country provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how future co-operation could be designed in a manner that respects the independence and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but suggested that talks must proceed considering a large portion of the nation's HIV programmes were funded by foreign aid.
"Where technical issues exist, such as those involving data governance or implementation frameworks, these can frequently be addressed via detailed discussion and mutually agreed protections," it said.
The halted deal emphasises the complex tensions between receiving vital international aid and protecting local interests in an increasingly interconnected world.